Which company developed Vemurafenib?

Vemurafenib is developed and produced by Roche Pharmaceuticals. Vemurafenibis an oral mutantBRAF-serine-threonine kinase inhibitor. Vemurafenib is a small molecule that interacts as a competitive inhibitor of BRAF mutant species. It is particularly effective against the BRAF V600E mutation. Vemurafenib blocks downstream processes to inhibit tumor growth and ultimately trigger apoptosis. Vemurafenibhas no antitumor effect on melanoma cell lines harboring wild-type BRAF mutations.

VemurafenibIt is well absorbed after oral administration. When patients took 960 mg orally twice daily for 15 days, peak concentrations were reached within 3 hours. Under the same conditions, the Cmax of vemurafenib is 62micrograms/ml, AUC is 601micrograms/ml. It is not clear from the label how food affects the absorption of vemurafenib. After repeated doses of 960mg, the accumulation rate was 7.361. Vemurafenibis highly bound to plasma proteins, with more than99% of the administered dose bound to serum albumin and α-1acidic glycoprotein. Vemurafenibis metabolized by CYP3A4, and its metabolites account for 5% of plasma composition. The parent compound makes up the remaining 95%.

Do not take after or immediately after a high-fat meal. Takingvemurafenib with a high-fat meal may increaseAUC and Cmax increase by approximately 5 times and 2.5 times respectively. Use grapefruit products with caution. Grapefruit inhibits the CYP3A4 metabolism of vemurafenib, which may increase its serum concentration. Use St. John's Wort with caution. This herb induces the CYP3A4 metabolism of vemurafenib and may decrease its serum concentration. Limit caffeine intake. VemurafenibVemurafenibinhibitsCYP1A2 which may increase caffeine serum levels and side effects. The Turkish version of the original medicine costs more than 2,000 per box.2 If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.